Drug Safety and Risk Management Advisory Committee
(DSaRM)
Slides
Overview
of Attention Deficit Hyperactivity
Disorder (ADHD) and its Pharmacotherapy |
Andrew Mosholder, M.D.,
M.P.H. Division of Drug Risk
Evaluation, Office of Drug Safety (ODS) |
Studying Cardiovascular Risk with Drug Treatments of ADHD |
Kate
Gelperin, M.D., M.P.H. Division of Drug Risk Evaluation,
ODS |
ADHD Drugs and Cardiovascular Outcomes: Preliminary Feasibility Study Results |
David
Graham, M.D., M.P.H. Associate Director for Science and Medicine, ODS |
Challenges of Studying Cardiovascular Outcomes in ADHD |
Elizabeth
Andrews, M.P.H., Ph.D. Vice President, Pharmacoepidemiology and Risk Management, Research Triangle Institute
Health Solutions |
Open
Public Hearing Speakers [PPT] |
|
|
A. J. Allen, M.D., Ph.D. Global Medical Director-Strattera Eli Lilly and Company |
|
M. Christopher Griffith, M.D. Children and Adults with Attention Deficit
Hyperactivity Disorder (CHADD) |
Introduction of Questions |
Gerald Dal Pan, M.D., M.H.S. Director, ODS |